Horan Capital Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $3.3M | Buy |
15,747
+94
| +0.6% | +$18.3K | 1.11% | 30 |
|
|
2024
Q4 | $2.78M | Sell |
15,653
-2,103
| -12% | -$387K | 0.94% | 37 |
|
|
2024
Q3 | $3.51M | Sell |
17,756
-185
| -1% | -$34.5K | 1.16% | 31 |
|
|
2024
Q2 | $3.08M | Sell |
17,941
-23
| -0.1% | -$3.81K | 1.08% | 32 |
|
|
2024
Q1 | $3.27M | Buy |
17,964
+86
| +0.5% | +$14.8K | 1.16% | 31 |
|
|
2023
Q4 | $2.77M | Buy |
17,878
+118
| +0.7% | +$17.2K | 1.02% | 38 |
|
|
2023
Q3 | $2.65M | Sell |
17,760
-505
| -3% | -$74.1K | 1.07% | 35 |
|
|
2023
Q2 | $2.46M | Buy |
18,265
+121
| +0.7% | +$17.7K | 0.96% | 35 |
|
|
2023
Q1 | $2.89M | Buy |
18,144
+215
| +1% | +$32.9K | 1.19% | 32 |
|
|
2022
Q4 | $2.9M | Sell |
17,929
-255
| -1% | -$39.1K | 1.27% | 32 |
|
|
2022
Q3 | $2.44M | Buy |
18,184
+383
| +2% | +$55K | 1.18% | 39 |
|
|
2022
Q2 | $2.73M | Sell |
17,801
-6,376
| -26% | -$974K | 1.27% | 35 |
|
|
2022
Q1 | $3.92M | Buy |
24,177
+138
| +0.6% | +$20K | 1.58% | 21 |
|
|
2021
Q4 | $3.25M | Sell |
24,039
-966
| -4% | -$114K | 1.29% | 31 |
|
|
2021
Q3 | $2.7M | Buy |
25,005
+612
| +3% | +$69.9K | 1.19% | 35 |
|
|
2021
Q2 | $2.75M | Buy |
24,393
+707
| +3% | +$79.6K | 1.24% | 34 |
|
|
2021
Q1 | $2.56M | Buy |
23,686
+435
| +2% | +$46.5K | 1.23% | 33 |
|
|
2020
Q4 | $2.49M | Buy |
23,251
+1,008
| +5% | +$96.9K | 1.29% | 31 |
|
|
2020
Q3 | $1.95M | Buy |
22,243
+404
| +2% | +$38K | 1.1% | 34 |
|
|
2020
Q2 | $2.14M | Sell |
21,839
-285
| -1% | -$25.1K | 1.44% | 26 |
|
|
2020
Q1 | $1.69M | Buy |
22,124
+362
| +2% | +$30.8K | 1.35% | 32 |
|
|
2019
Q4 | $1.93M | Sell |
21,762
-615
| -3% | -$51.1K | 1.14% | 40 |
|
|
2019
Q3 | $1.69M | Buy |
22,377
+50
| +0.2% | +$3.43K | 1.04% | 42 |
|
|
2019
Q2 | $1.62M | Buy |
22,327
+255
| +1% | +$20K | 1.09% | 40 |
|
|
2019
Q1 | $1.78M | Sell |
22,072
-2,185
| -9% | -$179K | 1.13% | 40 |
|
|
2018
Q4 | $2.24M | Sell |
24,257
-265
| -1% | -$23.3K | 1.5% | 31 |
|
|
2018
Q3 | $2.32M | Sell |
24,522
-600
| -2% | -$56.9K | 1.49% | 35 |
|
|
2018
Q2 | $2.33M | Sell |
25,122
-5,469
| -18% | -$534K | 1.49% | 29 |
|
|
2018
Q1 | $2.9M | Sell |
30,591
-36,126
| -54% | -$3.97M | 1.9% | 18 |
|
|
2017
Q4 | $8.55M | Buy |
66,717
+27,087
| +68% | +$2.55M | 5.56% | 3 |
|
|
2017
Q3 | $3.52M | Sell |
39,630
-51
| -0.1% | -$3.88K | 2.17% | 11 |
|
|
2017
Q2 | $2.88M | Sell |
39,681
-111
| -0.3% | -$7.46K | 1.96% | 19 |
|
|
2017
Q1 | $2.59M | Buy |
39,792
+410
| +1% | +$25.8K | 1.85% | 21 |
|
|
2016
Q4 | $2.47M | Buy |
39,382
+50
| +0.1% | +$3.05K | 1.84% | 22 |
|
|
2016
Q3 | $2.48M | Buy |
39,332
+605
| +2% | +$39.2K | 1.97% | 20 |
|
|
2016
Q2 | $2.4M | Buy |
38,727
+513
| +1% | +$31.3K | 1.95% | 19 |
|
|
2016
Q1 | $2.18M | Buy |
38,214
+3,220
| +9% | +$179K | 1.7% | 24 |
|
|
2015
Q4 | $2.07M | Sell |
34,994
-1,817
| -5% | -$105K | 1.73% | 25 |
|
|
2015
Q3 | $2M | Buy |
36,811
+963
| +3% | +$62.7K | 1.68% | 23 |
|
|
2015
Q2 | $2.41M | Sell |
35,848
-5,375
| -13% | -$351K | 2.03% | 19 |
|
|
2015
Q1 | $2.41M | Buy |
41,223
+1,780
| +5% | +$108K | 2.01% | 19 |
|
|
2014
Q4 | $2.58M | Buy |
39,443
+1,110
| +3% | +$70K | 2.13% | 11 |
|
|
2014
Q3 | $2.21M | Buy |
38,333
+5,589
| +17% | +$310K | 1.96% | 18 |
|
|
2014
Q2 | $1.85M | Buy |
32,744
+4,265
| +15% | +$224K | 1.69% | 23 |
|
|
2014
Q1 | $1.46M | Buy |
28,479
+3,020
| +12% | +$153K | 1.41% | 35 |
|
|
2013
Q4 | $1.34M | Buy |
25,459
+3,637
| +17% | +$179K | 1.37% | 35 |
|
|
2013
Q3 | $976K | Buy |
21,822
+1,830
| +9% | +$81.1K | 1.16% | 39 |
|
|
2013
Q2 | $826K | Buy |
+19,992
| New | +$874K | 1.26% | 37 |
|
Other funds holding ABBV
Horan Capital Advisors's ABBV Position: Q1 2025 in Review
Horan Capital Advisors increased its AbbVie (ABBV) stake by 0.6% in Q1 2025, buying an estimated $18.3K and bringing the position to 15,747 shares worth $3.3M. The position accounts for 1.11% of the portfolio, ranked #30.
Horan Capital Advisors first reported a position in ABBV in Q2 2013 and has held it in 48 quarters since. The position peaked at $8.55M in Q4 2017. 3,822 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.
- Horan Capital Advisors held 15,747 shares of AbbVie worth $3.3M as of Q1 2025.
- Horan Capital Advisors bought 94 AbbVie shares in Q1 2025, an estimated $18.3K.
- AbbVie made up 1.11% of Horan Capital Advisors's portfolio in Q1 2025, its #30 holding.
- Horan Capital Advisors first reported a position in AbbVie in Q2 2013 and has held it in 48 quarters since.
- Horan Capital Advisors's AbbVie position peaked at $8.55M in Q4 2017.
- 3,822 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.
Based on Horan Capital Advisors's 13F filing for Q1 2025, filed 7 May 2025.